EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson welcomes today\u2019s jury verdict in the company's favor in the Collins <\/i>case in Missouri State Court.<\/p>
\nThe facts here showed that the claims in this case were not supported by the science or experts in the medical community. Trial testimony underscored the complex, multifactorial nature of NEC and the important role specialized preterm hospital nutrition products continue to play in supporting vulnerable premature infants in the NICU.<\/p>
\nWe strongly reject any assertion that any of our specialized preterm hospital nutrition products cause NEC, a serious gastrointestinal condition that primarily affects premature infants. We will continue to vigorously defend ourselves against all other cases in the interest of safeguarding the health of premature babies.<\/p>
\nSpecialized preterm hospital nutrition products for premature babies provide essential, lifesaving nutrition to the most vulnerable infants when mother\u2019s or donor milk is unavailable or insufficient. For over 120 years, Mead Johnson has been committed to innovating advanced nutrition products to support even the most complex of dietary needs for all babies. We stand behind the safety and efficacy of our specialized preterm hospital nutrition products, which neonatologists recommend when clinically appropriate as part of the standard of care in neonatal intensive care units.<\/p>
\nNick Ashworth<\/b>